fiercebiotechSeptember 18, 2018
Tag: Epilepsy , rare diseases , Supernus
CNS drug specialist Supernus Pharma has added an early-stage epilepsy candidate to its pipeline after paying $15 million upfront to acquire Biscayne Neurotherapeutics.
Supernus is already a player in epilepsy with two marketed products based on new formulations of established drugs, but the merger with Biscayne Neurotherapeutics will give the company its only R&D project for this indication, slotting in alongside drugs for attention-deficit hyperactivity disorder, aggression, bipolar disorder and depression.
The takeover deal—which also includes development milestones of $73 million and another $95 million in the offing for hitting commercial targets—adds a drug for refractory forms of focal epilepsy based on a synthetic form of a compound called huperzine A which is found in traditional Chinese medicines used to treat seizures. The deal excludes rights to the drug in Asia, where it has been licensed out.
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: